GSN completes $20M financing round

Gene Security Network Inc. (GSN) today announced the completion of a $20 million financing round, as well as the change of the company's name to Natera, Inc. The financing round was led by Lightspeed Venture Partners, which is joined in the current round by Claremont Creek Ventures and Sequoia Capital.

"For me, our new name evokes birth, nature, and earth, and reflects our mission to help couples around the world manage pregnancies and reduce the risk of genetic disease," said Matthew Rabinowitz, Ph.D., CEO of Natera. "With proceeds from the funding and the extensive expertise of our team, we will continue to develop diagnostics that lead the industry in terms of the breadth, speed and reliability of information delivered to expecting couples at the early stages of pregnancy."

Ravi Mhatre, managing director of Lightspeed Venture Partners, added, "Lightspeed Venture Partners is delighted to have led this financing. We believe that Natera's testing services and expertise represent the future of prenatal diagnostics."

Proceeds from the financing will support the continued development and commercialization of the company's non-invasive prenatal diagnostic for Down syndrome and other genetic conditions. This includes the expansion of the NIH-funded clinical trial and preparing for commercial launch of the test in 2012.

"Non-invasive prenatal diagnosis is poised to redefine pregnancy management around the world," said Roelof Botha, partner at Sequoia Capital. "This additional financing and the launch of Natera's next product will fundamentally change the quality of prenatal care to help families have healthy children."

Added John Steuart, managing director at Claremont Creek Ventures, "We have been involved with Natera since its inception. With a steadfast focus on helping doctors give couples the best chance of having a healthy child, the company has successfully launched multiple products and has experienced tremendous growth in recent years. That is why we're very pleased to be part of this financing and look forward to seeing the company take the next step."

Source:

Gene Security Network Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Antiseizure medications during pregnancy linked to neurodevelopmental risks in children